LDL Established Target for Cardiovascular Risk

PCSK9 Mechanism of Action

Genetics PCSK9

PCSK9 Loss-of-function Mutations

PCSK9-Directed Therapies in Development

PCSK9 Monoclonal Antibodies

MENDEL Evolocumab Monotherapy for Hypercholesterolemia Study Design

MENDEL

MENDEL-2

ODYSSEY MONO Arilocumab Monotherapy for Hypercholesterolemia

PCSK9 Monoclonal Antibodies

PCSK9 Inhibition in Patients With Hypercholesterolemia Receiving Statin Therapy

Alirocumab on Top of Atorvastatin in Primary Hypercholesterolemia

LAPLACE-2 LDL-C Response at Mean of Weeks 10 and 12

PCSK9 Monoclonal Antibodies

GAUSS-1 Phase 2 Evolocumab in Statin-Intolerant Patients

GAUSS-1 % Change in LDL-C From Baseline at Week 12

GAUSS-2 Study Design Phase 3 Efficacy and Safety Study of Evolocumab in Statin-Intolerant Patients

GAUSS-2 % Change in LDL-C From Baseline at Week 12

PCSK9 Monoclonal Antibodies

Effect of Alirocumab on LDL-C in Heterozygous FH

RUTHERFORD Effect of Evolocumab on LDL-C in Heterozygous FH

RUTHERFORD-2

TESLA Trial Evaluating Evolocumab in Homozygous FH

PCSK9 Monoclonal Antibodies

DESCARTES Percentage Change in LDL-C From Baseline at Week 52 in Patients With Hypercholesterolemia

DESCARTES Evolocumab Safety at 52 weeks

OSLER Phase 3 Extension Study

OSLER Effect of Evolocumab on LDL-C after 52 Weeks

Alirocumab Trials ODYSSEY FH I and FH II Studies

FH I and FH II Results Over 52 Weeks

ODYSSEY Combo II Study

Combo II Results Over 52 Weeks

FH I, FH II, Combo II AEs Occurring in ≥ 5% of Patients

ODYSSEY Long-term Study Design

ODYSSEY Long-term Study LDL-C Reduction

ODYSSEY Long-term Study AEs

ODYSSEY Long-term Study* CV Death

OSLER Phase 3 Extension Study

OSLER Effect of Evolocumab on LDL-C after 52 Weeks

PCSK9 CV Outcomes Trials

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)